Diffuse Large B-cell Lymphoma Recurrent
5 drugs618 FAERS reportsMedDRA PT
GET
/api/v1/reaction/diffuse-large-b-cell-lymphoma-recurrentReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
Drugs reporting Diffuse Large B-cell Lymphoma Recurrent (5)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Tisagenlecleucel2074.6%
- 2Polatuzumab Vedotin3273.6%
- 3Mosunetuzumab283.4%
- 4Glofitamab502.4%
- 5Loncastuximab Tesirine61.7%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Diffuse Large B-cell Lymphoma5 shared · 0.63
- Hypogammaglobulinaemia2 shared · 0.20
- Cytopenia2 shared · 0.12
- Immune Effector Cell-associated Neurotoxicity Syndrome2 shared · 0.11
- Cytokine Release Syndrome4 shared · 0.11
- Neutrophil Count Decreased2 shared · 0.04
- Platelet Count Decreased4 shared · 0.03
- Febrile Neutropenia4 shared · 0.03
- Infection3 shared · 0.02
- White Blood Cell Count Decreased2 shared · 0.02
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.